DailyIQ
Last updatedjust now

CRL·Charles River Laboratories International, Inc.

$299.22
-2.64 (-0.87%)
Overnight$299.02-0.20 (-0.07%)
High
$303.15
Open
$301.00
Market Cap
14.30B
52W High
$333.30
Low
$295.15
P. Close
$299.22
P/E
-
52W Low
$146.19
Fwd P/E
23.41
DailyIQ Est.
$331.99
Inst. Ownership
63.1%
Short Interest
6.02%
Days to Cover
2.7
Technical Score (1D)
89
BULLISH
News Sentiment
59
BULLISH
On Oct 13, Charles River Laboratories announced that it would collaborate with Magellan Stem Cells to evaluate a novel osteoarthritis therapy. The partnership involved preclinical testing of the stem cell‑derived product in relevant animal models. The collaboration expanded CRL’s portfolio in regenerative medicine and could position the company for future clinical development opportunities. The announcement was reported as a modest positive development for CRL’s research pipeline.
LOW TARGET
$145 -51.5%
1 analysts
MEAN TARGET
$313 +4.7%
15 analysts
HIGH TARGET
$357 +19.4%
9 analysts
PRICE RANGE
$145.00 - $357.00
SB / B / H / S / SS
6/11/6/1/1
DAILYIQ EST.
$331.99 (+11.0%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Website
Symbol
CRL
Description
Charles River Laboratories International (CRL) is a global provider of essential services for the pharmaceutical and biotechnology industries. The company operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. CRL's RMS segment supplies research models, including rodents, and related services that support preclinical drug development. The DSA segment focuses on early-stage discovery, including target identification and safety assessment, offering services like toxicology and drug metabolism analysis. Finally, the Manufacturing segment provides quality control testing for pharmaceuticals and consumer products, including specialized testing for biologics. With strategic collaborations and alliances, CRL offers a comprehensive suite of services to support the entire drug development lifecycle, from initial research to manufacturing.
Bought (1Y)
10 shares
$3K
Sold (1Y)
175,091 shares
$44.3M
Parisotto Shannon MCEVP, Disc & Safety Assessment
Option Exercise981 shares2026-10-05
Parisotto Shannon MCEVP, Disc & Safety Assessment
Sell981 shares2026-10-05
Parisotto Shannon MCEVP, Disc & Safety Assessment
Option Exercise981 shares2026-10-05
Coleman GlennEVP & Chief Financial Officer
Buy10 shares2026-09-30
FOSTER JAMES C-
Option Exercise12,429 shares2026-08-25
55/ 100
Neutral / mixed
Overall: Neutral
✕Revenue declining year over year
✕Negative net margin
✓Positive operating cash flow
Net Margin
-3.6%
Revenue CAGR
6.9%
Current Ratio
1.29x
Debt / Equity
0.68x
Return on Equity
-4.6%
Earnings Summary
Charles River Laboratories International (CRL) is a global provider of essential services for the pharmaceutical and biotechnology industries, operating through Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments that support the entire drug development lifecycle. The company operates in the diagnostics and research sector, serving a highly specialized and regulated market. In the most recent two quarters, Q1 2026 and Q2 2026, CRL reported EPS of $2.06 and $3.02 respectively, both beating analyst expectations of $1.94 and $2.76, while revenue rose to $995.83 million and $1,004.08 million, slightly above the $987.26 million and $984.47 million estimates; this represents a modest acceleration in revenue growth compared to the prior two quarters where EPS grew from $2.34 to $3.12 and revenue increased from $984.17 million to $1,032.14 million. The company has consistently outperformed earnings estimates in the last four quarters, with EPS beats in all but the Q4 2025 quarter where EPS of $2.39 fell short of the $2.56 estimate, though revenue remained near estimate. Historically, CRL has shown a steady YoY revenue growth trajectory, with a 3.4% increase from Q4 2024 to Q4 2025 and a 1.8% decline in Q4 2025 to Q1 2026, yet EPS growth has remained robust, indicating efficient cost management. Recent news highlights the launch of Apollo Orchestrate on Oct 6, 2026, integrating digital laboratory execution into CRL’s Apollo platform, which could enhance operational efficiency and client transparency; this aligns with the company’s modernization strategy and may support future revenue stability.

EPS

EstBeatMiss
$1.77$2.15$2.53$2.91$3.30Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.97 - -
Q2'26$2.76$3.02+9.4%
Q1'26$1.94$2.06+6.0%
Q4'25$2.56$2.39-6.6%
Q3'25$2.34$2.43+3.9%
Q2'25$2.55$3.12+22.4%

Revenue

EstBeatMiss
$958M$979M$1000M$1.0B$1.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$968M - -
Q2'26$984M$1.0B+2.0%
Q1'26$987M$996M+0.9%
Q4'25$998M$994M-0.4%
Q3'25 - $1.0B -
Q2'25 - $1.0B -

Market Data

CRL Stock Snapshot

BULLISH89/100
$299.02−$0.20 (0.1%)
Market cap
14.30B
Day range
$295.15 – $303.15
News sentiment
59/100 · Neutral
Analyst target
$313.20 (+4.7%)
Consensus
Buy · 25 analysts
52-week range+104.5% off low · -10.3% from high
$146.19$333.30
Price $299.02 DailyIQ Est. $331.99

CRL's technical picture is constructive, with trend and momentum pointing the same direction. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into CRL?

RICH

At today's price, Charles River Laboratories International, Inc. needs to grow free cash flow about 23.9% a year for the next 10 years to justify its valuation at a 9.89% cost of capital. Over its actual history it has compounded free cash flow at 10.1% a year, so the market is asking for 13.9 percentage points above its own delivered rate. On that basis CRL looks priced above what its own growth record supports.

Implied FCF growth
23.9%
Historical FCF CAGR
10.1%
Growth gap
+13.9 pts
Verdict
RICH
Discount rate (WACC)
9.89%
Beta
1.09

Behaviour On Record

What CRL's own history says about today's numbers

Realized volatility (21d)
38.4% 74th pct
Below its peak
-34.2%
vs 200-day average
+42.2%
Up days (1y)
54%

Charles River Laboratories International, Inc. is currently running 38.4% annualised volatility over the last 21 sessions. Measured against CRL's own 13 years of daily returns rather than a market-wide average, that is the 74th percentile — a little above its own norm, against a typical reading of 29.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CRL is trading -34.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -25.2%, and the deepest was -49.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +42.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 99th percentile — a wider gap than this stock usually carries. Over the past year CRL closed higher on 54% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, CRL finished the month higher 8 of 13 times, with a median return of +3.4% and an average of +0.1%. Its strongest month historically has been July at +6.8% on average, its weakest April at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CRL has opened more than 2% away from the prior close in 168 of 3,266 sessions (5.1% of the time), with the largest gaps running +7.1% and -13.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CRL moved an average of 2.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.4% and a largest of +3.9%.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against CRL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CRL's sector?

Charles River Laboratories International, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for CRL?

CallsPuts

For Charles River Laboratories International, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.33), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.1% move by that expiry — a range of about $301.69–$302.03.

Put/call ratio (2026-10-16)
0.33
ATM implied volatility
0.8%
Total open interest
4
Expected move by 2026-10-16
±0.1% ($301.69–$302.03)

Analyst Rating Changes

Are analysts turning bullish or bearish on CRL?

Morgan Stanley most recently reiterated its rating on Charles River Laboratories International, Inc. to Overweight on Oct 13, 2026 with a price target of $340 (from $300). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
Morgan Stanley — Overweight
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026Morgan StanleyMaintainedOverweight$300 → $340
Sep 28, 2026JefferiesMaintainedBuy$305 → $340
Sep 25, 2026Deutsche BankMaintainedBuy$300 → $320
Sep 25, 2026TD CowenMaintainedBuy$300 → $325
Sep 25, 2026Evercore ISI GroupMaintainedOutperform$320 → $330
Sep 25, 2026RBC CapitalMaintainedOutperform$282 → $322
Sep 25, 2026BarclaysMaintainedOverweight$300 → $330
Sep 25, 2026MizuhoMaintainedNeutral$264 → $295
Sep 25, 2026BairdMaintainedOutperform$291 → $334
Sep 11, 2026Evercore ISI GroupMaintainedOutperform$300 → $320
Aug 10, 2026TD CowenMaintainedBuy$235 → $300
Aug 7, 2026Morgan StanleyMaintainedOverweight$260 → $300

Peers & ETF holders

CRL peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

59/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Charles River Laboratories announced a collaboration with Magellan Stem Cells to evaluate a novel osteoarthritis therapy. The partnership will involve preclinical testing of the stem cell‑derived product in relevant animal models. The collaboration expands CRL’s portfolio in regenerative medicine and could position the company for future clinical development opportunities. The announcement signals a modest positive development for CRL’s research pipeline.
What did this article say?
Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will release its third‑quarter 2026 financial results on November 4, 2026, before the market opens. A conference call to discuss the results is scheduled for the same day at 9:00 a.m. ET, with a live webcast and replay available on the company’s Investor Relations website. The announcement provides the timing of the earnings release and related investor communications but does not include any financial guidance or performance updates.
What did this article say?
Analysts compared Charles River Laboratories (CRL) with Progyny (PGNY) for value investors, noting CRL’s Zacks Rank of #3 (Hold) versus PGNY’s #2 (Buy). The assessment highlighted that CRL has seen a weaker improvement in earnings outlook compared to PGNY. Consequently, CRL was deemed less attractive for value-focused portfolios. The comparison underscored CRL’s relative underperformance in key value metrics, suggesting a modest headwind for the company. This evaluation may influence investor sentiment toward CRL’s valuation prospects.
What did this article say?
Charles River Laboratories (CRL) experienced a 75.8% share price increase over the past year, driven by improving Research Models and Services (RMS) performance, expansion of AI-enabled testing capabilities, and robust cash flow that supports buybacks and investment. The company’s diversified portfolio across discovery, safety assessment, and manufacturing solutions has positioned it well against industry peers, which grew only 10.5% during the same period. Strong fundamentals and a favorable outlook have reinforced investor confidence, contributing to the significant upside in CRL’s valuation.
What did this article say?
Charles River Laboratories announced the launch of Apollo Orchestrate, a new feature within its Apollo platform that integrates Autolomous’s autoloMATE digital laboratory execution system. The integration digitizes and automates laboratory workflows across North American and European sites, enhancing quality control in GMP environments. The move supports the company’s strategic commitment to modernize lab operations and improve client-facing transparency.
What did this article say?
Charles River Laboratories International (CRL) announced a partnership with Autolomous to launch Apollo, a digital platform aimed at automating laboratory execution. The collaboration focuses on integrating Autolomous’s autonomous technology with CRL’s laboratory services to enhance data transparency and operational efficiency. By digitizing workflows, the joint effort seeks to improve client experience and reduce manual errors. The move underscores CRL’s commitment to expanding its digital and automation capabilities in the life‑science sector.
What did this article say?
Charles River Laboratories lifted its fair‑value estimate to $305 following its investor and analyst days, with multiple research houses raising price targets into a $260–$330 range. The revisions reflect a more optimistic view of the company’s long‑range plan and margin goals. The upward re‑pricing signals a positive market consensus and may support a higher valuation for the stock.
What did this article say?
Analysts updated their consensus price target for Charles River Laboratories International (CRL) upward by 11.46%, setting it at $307.39. The revision reflects expectations of stronger earnings and continued growth in the contract research services sector. The new target suggests that market participants view CRL’s business model favorably and anticipate solid performance in the coming quarters. This adjustment is likely to influence investor perception and could support a modest rally in the stock price. The update underscores confidence in CRL’s ability to generate revenue growth amid a competitive landscape.
What did this article say?
The press release highlighted a projected rise in the global animal model market to $3.6 billion by 2032, driven by CRISPR, AI, and humanized models. Charles River Laboratories (CRL) is positioned to benefit from increased demand for animal models in drug and vaccine research. The growth is supported by rising biomedical research investment and a higher prevalence of chronic diseases. CRL’s role as a leading provider of animal models suggests a positive impact on its business prospects. The report underscores the company’s strategic alignment with emerging technologies in the life‑science sector.

Technical Analysis

Real-time indicators across multiple timeframes

89
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.64B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy5,887,17512.31%$1.17B2026-01-29
FMR LLC (Fidelity)▲ Buy4,239,7528.86%$961.53M2026-08-13
BlackRock, Inc.▼ Sell3,798,5607.94%$861.48M2026-08-07
Invesco Ltd.▲ Buy2,984,7856.24%$676.92M2026-08-14
Harris Associates L P▲ Buy2,241,1444.69%$508.27M2026-08-14
Geode Capital Management, LLC▲ Buy1,305,7382.73%$295.60M2026-08-12
Wellington Management Group LLP▼ Sell1,288,4632.69%$292.21M2026-08-14
Citadel Advisors LLC▼ Sell1,193,6012.50%$270.70M2026-09-02
Bank of America Corp▲ Buy1,172,5862.45%$265.93M2026-08-14
Neuberger Berman Group LLC▼ Sell862,7041.80%$195.63M2026-08-13
Morgan Stanley▼ Sell800,4871.67%$181.54M2026-08-13
Goldman Sachs Group Inc▲ Buy639,8031.34%$145.10M2026-08-14
Millennium Management LLC▼ Sell486,4621.02%$110.32M2026-08-14
Northern Trust Corp▲ Buy446,0920.93%$101.17M2026-08-13
Gotham Asset Management, LLC▲ Buy433,1460.91%$98.23M2026-08-14
Norges Bank▼ Sell370,0400.77%$83.92M2026-08-12
Marshall Wace, LLP▲ Buy342,9950.72%$77.79M2026-08-13
Citigroup Inc▲ Buy316,2170.66%$71.71M2026-08-03
JPMorgan Chase & Co▲ Buy286,3170.60%$65.09M2026-08-12
AllianceBernstein L.P.▲ Buy374,5850.78%$64.62M2026-08-14
Loomis Sayles & Co L P▲ Buy223,6680.47%$50.73M2026-08-14
Adage Capital Partners GP, L.L.C.▼ Sell213,4800.45%$48.42M2026-08-14
Wells Fargo & Company▲ Buy93,2250.19%$21.14M2026-08-14
AQR Capital Management LLC▼ Sell44,3440.09%$9.97M2026-08-14
Prudential Financial Inc▼ Sell32,4650.07%$7.36M2026-08-12
Q2 2026 flow:2.39M sh bought ($537.14M)1.09M sh sold ($248.20M)net +1.29M sh (+$288.94M)
Congressional Trading Activity
5 disclosed trades · ~$113.5K est. traded value · 3 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-05-082025-06-22
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-04-082025-05-08
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-152025-02-12